Sheila Gujrathi was appointed Director of Processa Pharmaceuticals, Inc. As of November 6, 2026, Processa Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to November 4, 2026, naming 1 appointment (Form 8-K, July 29, 2026).
Who owns Processa Pharmaceuticals, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Processa Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-04
- · In / out: In · Person: Sheila Gujrathi · Role: Director · 8-K, 2026-07-29
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-30
Processa Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-11-04. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Processa Pharmaceuticals, Inc. files it.
Also on the record for Processa Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 18, 2026 | Stake report, Schedule 13G, by Soleus Capital Master Fund, L.P. | 5.8% of the class | 5%+ stakes | Source |
| July 28, 2026 | Acquired Vidya Therapeutics, Inc. | $200M | Acquisition | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 7% of the class | 5%+ stakes | Source |
| February 23, 2026 | Stake report, Schedule 13D/A, by HX Entertainment Ltd | 13% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 8.1% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9% of the class | 5%+ stakes | Source |
| October 15, 2025 | Stake report, Schedule 13D/A, by Chiliz Group Ltd. | 10.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13D, by HX Entertainment Ltd | 10.9% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Processa Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Processa Pharmaceuticals, Inc. and the records around it.
Processa Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Acquisition Jul 2026
- Who owns it
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Processa Pharmaceuticals, Inc.
Get an email when Processa Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Processa Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Processa Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Processa Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Reported | not named in the filing | 8-K, 2026-11-04 | ||
| 2026-07-29 | In | Director | 8-K, 2026-07-29 | ||
| 2026-04-30 | Reported | not named in the filing | 8-K, 2026-04-30 |
Who leads Processa Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Sheila Gujrathi, appointed (filed 2026-07-29).
New leaders reset buying decisions — get the Full Report on Processa Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Processa Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Processa Pharmaceuticals, Inc.Every change, in the filing's words
Reported
Appointment of Gregory J. Flesher On November 2, 2026, the Board approved the appointment of Gregory J. Flesher as Chief Operating Officer of the Company, effective November 4, 2026 (the " Start Date ").
- In connection with Mr. Flesher's appointment as Chief Operating Officer, the Company entered into an employment letter with Mr. Flesher (the "Flesher Agreement"), which provides that Mr. Flesher is entitled to an annual base salary of $700,000 and a discretionary target bonus amount up to 60% of his annual base salary beginning in fiscal year 2027.
- The board of directors of the Company (the "Board") intends to make an option grant to purchase shares of Company's common stock, par value $0.0001 per share (the "Common Stock") equal to 3.0% of the Company's fully-diluted outstanding capital stock (the "Option") as of the date of grant, at an exercise price per share equal to the fair market value of a share of Common Stock on the date of grant, as determined by the Board.
- Such option grant shall be made at a later date following the conclusion of the Company's Special Meeting of Stockholders (the "Conversion Special Meeting") and contingent upon the approval by the Company's stockholders of the Company's 2027 Equity Incentive Plan (the "2027 Plan Proposal").
- For a description of the 2027 Plan Proposal, please refer to the Company's preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 9, 2026 (the "Conversion Preliminary Proxy Statement").
Appointed: Sheila Gujrathi, Director
Appointment of Directors In accordance with the Merger Agreement, on July 28, 2026, effective immediately after the First Effective Time, Sheila Gujrathi was appointed to the Board as a director.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Sheila Gujrathi, M.D., age 55, has served as a member of our board of directors since July 2026.
- Dr. Gujrathi founded Vidya and served as its Executive Chair of the board of directors of Vidya from March 2023 until the Acquisition.
- She has served as founder and Chief Executive Officer of Prana Therapies since March 2023, and as founder and Executive Chair of the board of directors of Lila Biologics, Inc., a privately held biopharmaceutical company, since March 2023.
- Dr. Gujrathi has served as a member of the boards of directors of BlossomHill Therapeutics, Inc., a publicly held biopharmaceutical company, since May 2026, and Janux Therapeutics, Inc., a publicly held biopharmaceutical company, since March 2021.
- She has also served as Executive Chair of the board of directors of Generian Pharmaceuticals, Inc., a privately held biotechnology company, since May 2023.
- Dr. Gujrathi previously served as a member of the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen, Inc. in April 2021) from December 2015 to June 2019 and as a member of the board of directors of Ambrx, Inc., a then-publicly held biopharmaceutical company, from February 2014 until its acquisition by Johnson & Johnson in June 2015.
Reported
On April 30, 2026, Processa Pharmaceuticals, Inc. (the "Company") approved a transition in the employment status of Dr. Sian Bigora, the Company's Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
- Effective May 1, 2026, Dr. Bigora will transition from a full-time executive officer role to a part-time employee position.
- In connection with this change, she will no longer be designated as an "executive officer" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- She will, however, retain her title of Chief Development and Regulatory Officer and continue to provide services to the Company in a reduced capacity.
- In connection with this transition, Dr. Bigora's existing employment agreement with the Company will terminate and will be replaced by a new part-time employment arrangement effective May 1, 2026.
- Dr. Bigora will continue to be entitled to any equity awards previously granted to her, subject to the terms and conditions of the applicable equity plans and award agreements and will remain eligible to receive any previously awarded bonus compensation in accordance with its original terms.
Tools for this story
Each opens in a new tab, filled in for Processa Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.